Juan Pedro-Botet
Juan Pedro-Botet
In addition to low-density lipoproteins (LDL), those containing apolipoprotein (Apo) B and with a diameter less than 70 nm, including the smaller triglyceride-rich lipoproteins, remnant particles, and lipoprotein(a), may independently contr...
Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial [0.03%]
急性冠状动脉综合征后使用乙醇共轭二十碳五烯酸：REDUCE-IT试验
Neila Sayah,Deepak L Bhatt,Michael Miller et al.
Neila Sayah et al.
Randomized Controlled Trial
European heart journal. 2024 Apr 1;45(13):1173-1176. DOI:10.1093/eurheartj/ehad889 2024
Generalizability of the REDUCE-IT trial to South Asians with cardiovascular disease [0.03%]
REDUCE-IT试验对心血管疾病南亚人的普适性
Aishwarya Krishnaraj,Ehab Bakbak,Hwee Teoh et al.
Aishwarya Krishnaraj et al.
Background: South Asians (SAs) represent ∼25% of the world's population and account for >50% of global cardiovascular (CV) deaths, yet they continue to be underrepresented in contemporary clinical trials. The REDUCE-IT s...
Observational Study
Med (New York, N.Y.). 2023 Feb 10;4(2):130-138.e1. DOI:10.1016/j.medj.2022.12.008 2023
Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registry [0.03%]
关于心血管结局的普遍性REDUCE-IT试验以及潜在接受依洛尤单抗治疗的患者的高甘油三酯血症相关性：来自减少动脉栓塞以保持健康（REACH）登记处的一项分析
Fabien Picard,Deepak L Bhatt,Grégory Ducrocq et al.
Fabien Picard et al.
Background: The REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial) trial demonstrated that high-dose icosapent-ethyl reduced the risk of ischemic events in statin-treated patients with ...
Randomized Controlled Trial
International journal of cardiology. 2021 Oct 1:340:96-104. DOI:10.1016/j.ijcard.2021.08.031 2021
Applicability of the REDUCE-IT trial to the FAST-MI registry. Are the results of randomized trials relevant in routine clinical practice? [0.03%]
REDUCE-IT试验对FAST-MI注册研究的适用性。随机对照研究的结果能否指导日常临床实践？
Jean Ferrières,Vincent Bataille,Etienne Puymirat et al.
Jean Ferrières et al.
Background: The reduction of cardiovascular events with icosapent ethyl-intervention trial (REDUCE-IT) trial revealed robust atherosclerotic cardiovascular risk reduction with a strategy comprising high-dose omega-3 icosa...
Multicenter Study
Clinical cardiology. 2020 Nov;43(11):1260-1265. DOI:10.1002/clc.23437 2020
Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics [0.03%]
伊索醇酯在REDUCE-IT研究中显著降低首次及总心血管事件：本结果为何宣告脂质管理治疗新时代的到来
William E Boden,Deepak L Bhatt,Peter P Toth et al.
William E Boden et al.
The aims of this clinical review are to: (i) highlight the importance of elevated baseline triglycerides (TG) in the setting of well-controlled low-density lipoprotein cholesterol (LDL-C) on statins as a major contributor to residual athero...
Icosapent ethyl for hypertriglyceridemia: insights from the REDUCE-IT Trial [0.03%]
伊索莫德乙酯治疗高甘油三酯血症：REDUCE-IT研究启示
Michael Miller
Michael Miller
Cardiovascular, electrophysiologic, and hematologic effects of omega-3 fatty acids beyond reducing hypertriglyceridemia: as it pertains to the recently published REDUCE-IT trial [0.03%]
ω-3脂肪酸对心血管、电生理和血液系统的影响超越了降低高甘油三酯：关于最近发表的REDUCE-IT试验的相关性
Omar Sheikh,Anthony G Vande Hei,Ayman Battisha et al.
Omar Sheikh et al.
Heart disease continues to affect health outcomes globally, accounting for a quarter of all deaths in the United States. Despite the improvement in the development and implementation of guideline-directed medical therapy, the risk of advers...
Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial [0.03%]
基于REDUCE-IT试验的icosapent乙酯的适应症和费用分析
Xiaoming Jia,Julia M Akeroyd,Khurram Nasir et al.
Xiaoming Jia et al.
Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease [0.03%]
稳定型冠状动脉疾病患者中REDUCE-IT试验的适用性分析
Fabien Picard,Deepak L Bhatt,Grégory Ducrocq et al.
Fabien Picard et al.